24 July 2024
RUA Life
Sciences Plc
("RUA Life Sciences",
the "Company" or the
"Group")
New
Material Project Win
RUA Life Sciences (AIM: RUA),
the holding company of a group of medical device businesses focused
on the exploitation of the world's leading long-term implantable
biostable polymer (Elast-Eon™), announces a new contract win within
Contract Manufacture business unit.
RUA has received a purchase order
from an existing customer to undertake a short turnaround textile
processing project. The project will be delivered to the customer
over the next four months with a total contract value of over
£400,000. On delivery of the project, there is the potential for
conversion to a longer term supply contract for the processed
textile material.
Bill Brown, CEO of RUA Life
Sciences, stated: "Being awarded
this line of business from a major medical company is a testament
to the quality of product provided by RUA and the supporting
quality management system that provides our customers with the
confidence to place critical business with RUA."
The information communicated in this
announcement contains inside information for the purposes of
Article 7 of the Market Abuse Regulation (EU) No.
596/2014.
For
further information contact:
|
RUA
Life Sciences
Bill Brown, CEO
Lachlan Smith, CFO
|
Tel: +44 (0)1294 317073
Tel: +44 (0)1294 317073
|
|
Cavendish Capital Markets
Limited
(Nominated Adviser and Broker)
Giles Balleny/Dan
Hodkinson (Corporate Finance)
Charlie
Combe (Broking)
Michael
Johnson (Sales)
|
Tel: +44 (0)20 7220 0500
|
About RUA Life Sciences
The RUA Life
Sciences group was created in April
2020 when RUA Life Sciences Plc (formerly known
as AorTech International Plc) acquired RUA Medical
Devices Limited to create a fully formed medical device
business. RUA Life Sciences is the holding company of the
Group's four trading businesses, each exploiting the Group's
patented polymer technology.
Our vision is to improve the lives
of millions of patients by enabling medical devices with
Elast-EonTM, the world's leading long-term implantable polyurethane.
Whether it is licensing Elast-EonTM, manufacturing a device or
component, or developing next generation medical devices,
a RUA Life Sciences business is pursuing our
vision.
Elast-Eon™'s biostability is
comparable to silicone while exhibiting excellent mechanical, blood
contacting and flex-fatigue properties. These polymers can be
processed using conventional thermoplastic extrusion and moulding
techniques. With over 8 million implants and 15 years of successful
clinical use, RUA's polymers are proven in long-term life enabling
applications.
The Group's four business units
are:
|
RUA
Contract Manufacture:
|
End-to-end contract developer and
manufacturer of medical devices and implantable fabric
specialist.
|
|
RUA
Biomaterials:
|
Licensor of
Elast-EonTM polymers to the medical device
industry.
|
|
RUA
Vascular:
|
Commercialisation of open surgical
vascular grafts and patches
|
|
RUA
Structural Heart:
|
Development of polymeric leaflet
systems for heart valves.
|